Zhang K, Shah C, Graham C, McBayne T, Schultz B. A cost model comparing long-term prophylaxis options for hereditary angioedema: lanadelumab and berotralsta. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S39. doi: 10.18553/jmcp.2023.29.10-a.s1
Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis in Brazil. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S240. doi: 10.1016/j.jval.2018.04.1633
Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.
Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.
Maiese E, Graham CN, Hawe E, Le Moine JG. Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma. Poster presented at the 2018 ASCO Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; p.e20037. doi: 10.1200/JCO.2018.36.15_suppl.e20037
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711
Graham CN, McBride D, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Augustin M. Cost-effectiveness of secukinumab in moderate to severe psoriasis compared with other biologics in Germany. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A157.
Augustin M, Graham CN, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, McBride D. A cost-per-responder analysis of secukinumab compared with ustekinumab through 52 weeks in Germany: results from the clear study of patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A158.
Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, McBride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.
Augustin M, Krieger T, McBride D, Graham C, Melzer N, Kneidl J, Gutknecht M, Neidhardt K. Kosten-effektivität von secukinumab in der induktionstherapie der psoriasis in Deutschland. Poster presented at the 49th German Society of Dermatology (DDG) Conference; April 26, 2017. Berlin, Germany. [abstract] J Dtsch Dermatol Ges. 2017 Apr; 15(S1):130-1. doi: 10.1111/ddg.13213
Feldman S, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3-a):S84.
Augustin M, Krieger T, McBride D, Graham CN, Melzer N, Kneidl J, Neidhardt K. Cost-effectiveness of secukinumab as first biologic treatment for psoriasis compared with initiating other biologic therapy in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A568-9.
Halliday A, Hacking V, Jugl SM, Gunda P, Nikoglou E, Miles L, Graham CN. Budget impact of secukinumab for ankylosing spondylitis in the UK. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A535.
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling psoriatic arthritis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A233-4.
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).